Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Citius Pharmaceuticals, Inc. (CTXR : NSDQ)

• Company Description    Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $1.21 Daily Weekly Monthly 20 Day Moving Average: 465,642 shares Shares Outstanding: 17.01 (millions) Market Capitalization: $20.58 (millions) Beta: 1.35 52 Week High: $15.25 52 Week Low: $0.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.63% -9.26% 12 Week 32.59% 20.44% Year To Date -69.75% -73.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11 Commerce Drive First Floor - Cranford,NJ 07016 USA ph: 908-967-6677 fax: - ir@citiuspharma.com http://www.citiuspharma.com

• General Corporate Information    Officers Leonard Mazur - Chief Executive Officer and Director Myron Holubiak - Executive Vice Chairman and Director Jaime Bartushak - Chief Financial Officer Suren Dutia - Director Carol Webb - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 17322U306 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 06/01/25 Next Expected EPS Date: 12/26/25 Share - Related Items Shares Outstanding: 17.01 Most Recent Split Date: 11.00 (0.04:1) Beta: 1.35 Market Capitalization: $20.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/26/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.26 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 46.67% vs. Previous Quarter: 37.01% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -60.03 03/31/25 - -58.63 12/31/24 - -51.69 ROA 06/30/25 - -33.83 03/31/25 - -37.67 12/31/24 - -37.60 Current Ratio 06/30/25 - 0.47 03/31/25 - 0.37 12/31/24 - 0.41 Quick Ratio 06/30/25 - 0.14 03/31/25 - 0.06 12/31/24 - 0.09 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 4.67 03/31/25 - 6.47 12/31/24 - 8.02 Inventory Turnover 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©